Teknova Raises 2026 Revenue Outlook After Record Quarter

The Tip Desk · November 11, 2026 · 3 min read

Third-quarter revenue reached $12.7 million, up 22%, and the company now expects full-year sales of $46 million to $48 million.

Alpha Teknova, Inc. (TKNO), a producer of critical reagents for the life sciences industry, reported third-quarter 2026 revenue of $12.7 million, up 22% from $10.5 million a year earlier, after 18% year-over-year growth in the second quarter.

The company said the increase marked a second consecutive quarter of record revenue. President and Chief Executive Officer Stephen Gunstream attributed growth to higher sales of products to life science tools and diagnostics and to biopharma customers, and said purchases of custom products by small and mid-sized biotech customers and their contract manufacturers rose, which the company described as an early indication of biotech funding improvements over the past four quarters.

Clinical Solutions was the faster-growing reportable line. That segment’s revenue was $3.2 million, up 86% from $1.7 million in the third quarter of 2025, after 18% year-over-year growth in the second quarter. Lab Essentials revenue was $9.0 million, up 9% from $8.3 million a year earlier, after 18% year-over-year growth in the second quarter. Other revenue was $502,000.

Gross profit was $4.8 million, and gross margin was 38.0%, compared with 30.7% a year earlier. The company said the margin increase was primarily driven by higher revenue and, to a lesser extent, lower fixed cost absorption into cost of goods sold from changes in finished goods inventory levels, partially offset by higher variable costs. Gross margin had been 40.1% in the second quarter.

Operating expenses were $8.0 million, compared with $7.2 million a year earlier. The company said the increase was primarily driven by higher sales and marketing spending from higher headcount, coupled with slightly increased general and administrative expenses, partially offset by lower stock-based compensation.

Net loss was $3.5 million, or negative $0.06 a share, compared with $4.3 million, or negative $0.08 a share, a year earlier. Adjusted EBITDA was negative $1.0 million, compared with negative $1.6 million a year earlier. Cash used in operating activities was $1.3 million, and Free Cash Outflow was $1.4 million, compared with $2.4 million a year earlier.

Teknova raised its fiscal 2026 revenue outlook to $46 million to $48 million from the $45 million to $47 million range set after the second quarter. It continues to anticipate Free Cash Outflow of less than $8 million for the year ending December 31, 2026.

On October 22, 2026, the company closed an underwritten public offering of 9,200,000 shares, including full exercise of the underwriters’ option, at $5.00 a share, for gross proceeds of $46.0 million and net proceeds of approximately $42.9 million. Chief Financial Officer Matt Lowell said the offering added flexibility to the balance sheet and brought a significant number of new investors into the shareholder base. The company had announced the proposed offering in late October and said it currently intended to use net proceeds for general corporate purposes, including potentially the repayment of outstanding debt.

Total cash and short-term investments were $16.6 million and total borrowings were $13.2 million at the end of the third quarter. Teknova also launched the Fill-Tek Dispensing System to expand its modular manufacturing platform, which it said provides greater flexibility for customers to order single-use bag sizes, quantities, and fill volumes across RUO, RUO+, and GMP grades.